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Neodymium: YAG Laser Therapy for 
Palliative Treatment of Penile Kaposi's Sarcoma 
Kenneth I. Wishnow 
Though laser therapy has had 
long-standing success in 
opthalmology and dermatol-
ogy, its use in other fields is 
just beginning. Recently, two 
M. D. Anderson urologists, 
Kenneth I. Wish now, M. D., 
and Douglas E. Johnson, 
M. D., were the first to treat 
penile Kaposi's sarcoma lesions 
with a neodymium:YAG 
(yttrium, aluminum, garnet) laser. 
' 'The neodymium:YAG laser has a lot of potential, espe-
cially in regard to the palliative treatment of patients with 
AIDS (acquired immune deficiency syndrome) . The 
patient we treated, like other AIDS patients, developed 
Kaposi's sarcoma. Though we could not cure his systemic 
disease, we successfully treated a local manifestation of it, " 
said Wish now. 
Like all lasers, the neodymium: YAG laser precisely deliv-
ers high energy to a discrete area, removing diseased tissue 
while preserving normal tissue. But what distinguishes the 
neodymium: YAG from most other lasers, Wish now said, 
is its versatility. The neodymium: YAG laser, unlike the 
more conventional CO2 laser, has a wavelength suitable 
for endoscopic use, and thus can be used to treat internal 
tumors, such as those of the bladder. "It also has more tis-
sue penetration and results in less bleeding," he said. 
These advantages were important factors in deciding to 
use the neodymium: YAG laser for this patient, Wish now 
said. "We could have used a CO2 laser, but since we didn't 
know how deep the lesion was, we felt the better tissue 
penetration of the neodymium: YAG laser would result in a 
deeper surgical margin and therefore reduce the possibility 
ofrecurrence. And because the penis is a very vascular 
region, we were worried about bleeding. Though we could 
have used it for the topical lesion, the CO2 laser cannot 
penetrate fluid as effectively. This makes it more difficult 
to cauterize underlying blood vessels ." 
The patient had a topical lesion on the glans penis adja-
cent to the urethral meatus, which was easily photoablated, 
but the patient also had a second lesion in the fossa navicu-
laris inside the urethra. To direct laser therapy to that lesion, 
Wishnow and Johnson used a gastrointestinal optic fiber 
passed through a panendoscope. 
Though laser therapy was not the only possible form of 
treatment for this lesion, it clearly was superior in terms of 
morbidity, Wishnow said. "Radiation therapy might have 
resulted in a deformity of the penis, and open surgery-a 
total or partial penectomy-would have had a negative psy-
chological impact on the patient. " 
continued on page 2 




Alternative Treatments Sometimes Necessary 
Wishnow emphasized that such treatments are some-
times necessary, as in the case oflocal disease that has the 
potential to metastasize. "If a potentially metastatic lesion 
is locally curable, then initial treatment must be aggressive, 
but in this case the patient had AIDS and thus a higher risk 
of developing infection as a result of open surgery. More-
over, the penile lesion was a local manifestation of a sys-
temic disease, so we could 'undertreat' the patient in the 
sense that, if the lesion recurred, we could simply photo-
ablate the lesion again." 
The potential for metastasis was not a principal concern 
in this case, but if the lesion had been a local carcinoma 
with the potential to micrometastasize, then the patient 's 
survival would have hinged on complete eradication of the 
disease. If this had been the case, then alternative treat-
ments might have been necessary. 
'' Because the neodymium: YAG laser had never been 
used on a penile Kaposi's sarcoma lesion, we really didn ' t 
know how likely the lesions were to return," Wishnow 
said. However, to date, the lesions have not recurred in the 
treated area, though other penile lesions have appeared in 
untreated areas. If this form of therapy is as successful in 
other patients, then the neodymium: YAG laser may play 
an important role in palliative treatment for Kaposi's sar-
coma, he said. 
Reduced Morbidity 
In this case, a local manifestation of systemic disease had 
compromised an organ's function. The Kaposi's sarcoma 
lesion had made urination painful and difficult. 1reatment, 
therefore, was directed at preserving the organ's function at 
the least possible cost-both physically and psychologically-
to the patient, Wishnow said. "After treatment, the 
patient reported no pain. Two or three days later he was 
able to urinate well. One week later, the treated areas 
showed tissue necrosis and minimal edema but no infec-
tion. The remarkable thing about laser therapy is that, even 
though there seems to be a lot of destruction on the sur-
face, actual penetration is only a few millimeters. Though 
the epithelium is destroyed, the underlying tissue is pre-
served," Wishnow said. 
Wishnow emphasized that in addition to reducing mor-
bidity, the procedure is less expensive than other forms of 
surgery. "This patient was treated as an outpatient. The 
procedure was performed in less than an hour and the 
patient went home the same day. Use of the laser is expen-
sive, but this cost is more than offset by eliminating the 
5- to 7-day hospitalization. This is significant, considering 
that penile Kaposi's sarcoma, though once rare, is increas-
ing in frequency as a result of AIDS." 
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Other Uses for Laser Therapy 
Laser therapy is currently available in many community 
hospitals and can be used to treat noncancerous lesions as 
well, according to Wish now. ''Lesions of the external geni-
talia, such as condyloma acuminatum, can very easily be 
treated on an outpatient basis. " 
Wishnow cautioned, however, that a confirmed diagnosis 
is necessary before using laser therapy. "It is often neces-
sary that a biopsy be performed so that histologic examina-
tion can confirm the diagnosis . If a lesion that is perceived 
to be benign is destroyed when in fact it was a carcinoma, 
you 're putting the patient at risk for metastasis. If you 
eliminate the lesion before biopsy, obviously you're elimi-
nating the only means of confirming the diagnosis." 
Aside from ophthalmologic and dermatologic applica-
tions, which have become well established, laser therapy is 
being explored for treating gynecologic, gastrointestinal, 
cardiac, neurologic, thoracic, orthopedic, and head-and-
neck diseases, according to Wish now. '' If applications in 
other fields have analogous results, then laser therapy, in 
general, may ~nd up costing the patient less. The irony 
of this treatment is that the laser itself is a very expensive 
piece of equipment, but the decreased morbidity from 
such treatment has other benefits, such as reducing-or 
eliminating-the need for inpatient care. In my field, 
whether laser therapy can effectively replace open surgery 
remains to be seen, but in terms of palliative treatment for 
local disease, its prospects are promising." ■ 
Physicians wh<;> desire additional information may write Kenneth I. 
Wishnow, M .D., Department of Urology, Box 110, The University of 
Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, 
Houston , Texas 77030, or call (713) 792-3250 . 
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New Range of Fungal Infections Seen 
in Cancer Patients 
l 
Elias J. Anaissie 
Species of the fungi Candida 
and Asper;gillus sometimes 
cause opportunistic fungal 
infections in cancer patients. 
Recently, however, severe 
infections of this type were 
traced to newly recognized 
fungi such as Fusarium, Tricho-
sporon, Bipolaris, Geotrichum 
candidum, Cunninghamella, 
Curvularia, Pseudalescheria 
boydii, and others, according to Elias J. Anaissie, M.D., 
assistant professor in the Section oflnfectious Diseases at 
The University ofTexas M. D. Anderson Cancer Center. 
Patients who are profoundly neutropenic and remain so 
for several weeks are most often affected-especially those 
with hematologic malignancies such as acute myelogenous 
leukemia and those receiving bone marrow transplants . 
The main predisposing factors for the development of these 
infections include bone marrow suppression, use ofbroad-
spectrum antibiotics, disruption of the integrity of the skin 
and mucous membranes, and the use of immunosuppres-
sive drugs. A few fungal infections have been related to the 
use of central venous catheters. 
Infections Difficult to Diagnose 
Ranging from minor to life-threatening ones involving 
multiple organs, these infections are usually disseminated, 
especially in severely neutropenic patients. 
" Unfortunately, the diagnosis of these infections may be 
quite difficult," Anaissie said. "Neutropenic patients may 
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not develop the classic signs and symptoms of infection 
because of the lack of inflammatory response. The only 
sign of infection may be a fever not responsive to adequate 
and broad-spectrum antibiotics.'' 
Some of the isolates present as sinusitis, especially Fusar-
ium, Bipolaris, and Curvularia; this suggests that the organ-
isms are inhaled through the airways and " should alert us 
to the possibility that sinus infection in the immunocom-
promised patient could be caused by one of these organ-
isms, " he said. 
Signs and Symptoms of Most Common Fungi 
Most commonly encountered in recent experience are 
Trichosporon beigelii and Fusarium species (see photographs). 
Disseminated Trichosporon, nodular infarct with hyphae, arthroconidia, and a few yeasts . 
T beigelii is a saphrophytic organism often found on 
the skin; it causes infection only if the host's defenses are 
severely altered. Its clinical presentation is similar to that 
continued on page 6 
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Knowing How Normal Cells Differentiate Will Add 
Rationality to Stopping Cancer Cells 
William J. Lennorz 
By what biologic principles is 
cancer connected to embry-
onic development? 
William J. Lennarz, Ph.D., 
chairman of the Department 
of Biochemistry and Molecular 
Biology, speaks in questions 
and answers, which are the 
rhythm of his work, and he 
makes clear quickly that those 
who study basic cancer mecha-
nisms are a long way from understanding them. 
He explained the connection between cellular develop-
ment of the embryo and cancer by describing the cellular 
process of the early stages oflife, the predifferentiated 
stages during which identical cells replicate rapidly. During 
differentiation, the next stage, cells begin to "differentiate 
into specific subtypes," he said. "They become brain cells, 
liver cells, and so on, and then their fate is sealed, their 
schedule set. They can keep increasing-in the human 
being until adolescence-and then begin a slow rate of 
turnover but no longer rapid growth. But if cancer 
develops, the cells return to a dedifferentiated stage of 
rapid multiplication that eventually results in a tumor." 
How Does a Cell Stop Differentiating? 
What happens in cancer, he said, probably in several 
steps, is that the differentiation program of a skin or kidney 
or brain cell becomes perturbed, causing the cell to revert 
to its primitive form, to dedifferentiate. It starts losing 
some of its characteristic molecules. 
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"We ask, " Lennarz said, " why and how does that cell 
now lose its ability to maintain differentiation, its specific 
characteristics? And the bottom line is that if you put my 
back to the wall and ask me to describe the events, I can't 
do it because I don't understand normal growth nor does 
anybody else. Basically, then , we need to understand how 
growth is controlled before we can answer the question, 
What causes this cell to dedifferentiate and grow like crazy 
to form a tumor?" 
Sea Urchin a Useful Model 
An accessible model for studying these basic processes is 
the sea urchin embryo, Lennarz said, " because you can 
produce these embryos in very large numbers by mixing 
sperm and eggs in the test tube; you can have millions 
of them growing in synchrony-and perhaps even more 
important, you can benefit by the knowledge of people 
who have been studying the sea urchin embryo since the 
discovery of the microscope. ' ' 
One side of sea urchin embryo at 16-cell stage about five hours ofter fertilization. 
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Gostrula-stoge sea urchin embryo about 48 hours after fertilization, dry-fractured to 
expose differentiating cells (arrow) that form the primitive gut. Cells inside wall at left 
will form the skeleton . The embryo now consists of about 1000 cells . 
Flattened pluteus-stage embryo about 96 hours ofter fertilization, showing terminally 
differentiated cells that form the skeleton. 
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For hundreds of years, he said, "people have been peer-
ing at this organism, so we know which cell gives rise to 
which tissue. And it's simpler and cheaper and everything 
happens a lot faster than in the mammal. Some basic bio-
logic processes, for instance the formation of the intestine 
and the skeleton, have analogues in mammals, so this is a 
reasonable model system" (see photographs). 
In describing the process of differentiation, he said each 
kind of cell in the body has a sort of "fingerprint collection 
of molecules it makes." The liver cell produces serum 
albumin to be pumped into the serum to carry lipids and 
other components, and it produces transferrin, which picks 
up iron to be returned to the cells . "So the liver cell has a 
pattern of molecules it makes, controlled by a set of genes-
which are the same in all the cells of the whole organism, 
but the genes turned on in the liver cell are different from 
those in, say, the skin cell. " During this process the cell 
involved in cancer reverts back to the earlier stage of rapid, 
seemingly uncontrolled multiplication. 
Muscle to Mouse 
Lennarz is the first chairman of his department, having 
come here five years ago from Johns Hopkins University 
School of Medicine where he was a professor in the depart-
ment of biological chemistry. At the M. D. Anderson 
Cancer Center, he is the Robert A. Welch professor of 
chemistry. His department has 110 staff members, includ-
ing 11 faculty members, 25 graduate students, and 35 
postdoctoral trainees. All are engaged in studying one or 
another aspect of cell differentiation because what Lennarz 
calls the shotgun approach to cancer, to stopping abnormal 
growth, will not be totally replaced by more rational meth-
ods until the riormal processes are known. 
So, for example, Eric N. Olson, Ph.D., works on differ-
entiation of muscle and other cells; Daniel D. Carson, 
Ph.D., on how the mouse embryo becomes attached to 
continued on page 8 
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Fungal Infections continued trom page 3 
of disseminated candidiasis, which frequently causes meta-
static skin lesions. These lesions may be diagnosed by 
biopsy examination. "For diagnosis and therapy, it is use-
ful to know that Trichsporon shares common antigenic 
determinants with Cryptococcus neoformans. If you get a 
,.,,.*_ 
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. t ~ 
Acute branching septate hyphae of Fusarium in lungs. 
positive antigen for Cryptococcus in a cancer patient with 
unexplained fever and without evidence of cryptococcal 
infection, it is likely that the patient is infected with Tri-
chosporon,'' said Anaissie. 
Fusarium species, fungal organisms commonly present in 
nature, were responsible in World War II for intoxicating 
millions of people who ingested contaminated food. But 
infections are rare and have been noted only recently, pri-
marily in cancer patients. Fusarium tends to cause skin 
lesions similar to those of aspergillus infections and, unlike 
Aspergillus, Fusarium can be cultured from blood, Anaissie 
explained. 
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''Several of the newly recognized fungi look.like Aspergil-
lus or Candida in tissue. The only way to distinguish them 
from commonly encountered fungi is to obtain a culture," 
he said . Culture specimens should be obtained from any 
site of potential infection, including blood, sputum, urine, 
and bone marrow, but blood culture will not yield the fun-
gus in the majority of cases. Serum blood tests for detect-
ing fungal antigens are currently being developed but are 
not yet clinically applicable. 
Drug Resistance and Susceptibility 
Cunninghamella, Trichosporon, and Pseudalescheria boydii 
tend to resist amphotericin B, the drug most commonly 
used to treat candidiasis and aspergillosis, making identifi-
cation of the pathogen and establishment of drug sensitiv-
ity critical for the management of these patients. 
Amphotericin B remains the treatment of choice unless 
the offending organism has been shown to be resistant 
to this drug and susceptible to other drugs or drug 
combinations. 
A new approach to preventing aspergillus pneumonitis 
may be the use of aerosolized intranasal amphotericin B, 
which has been shown in a limited series to prevent the 
development of this life-threatening infection. 
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Use of the drug 5-flucytosine, in combination with 
amphotericin B, has been advocated for treatment of dis-
seminated candida infections, " but studies to support its 
use are lacking," said Anaissie. Other possible drugs for 
treating these fungal infections are miconazole and some 
other newly described azoles such as itraconazole or flu-
conazole. But these drugs are fungistatic only and have not 
been adequately studied in cancer patients. 
Neutrophil Count Most Important 
" The patients' neutrophil count is the most important 
factor in their recovery from fungal infections," said 
Anaissie. "By using granulocyte-macrophage colony-
stimulating factor (GM-CSF), we try to shorten the dura-
tion of neutropenia in patients and thus either prevent or 
treat some of these infections.'' 
In addition , said Anaissie, other newly developed anti-
fungal drugs are under investigation for their potential as 
prophylactic agents fo r fu ngal infections . ■ 
Physicians who desire additional info rmation may write Elias J. Anaissie, 
M .D. , Section of Infectious Diseases, Box 47, The University of Texas 
M . D. Anderson Cancer Center, 1515 Holcombe Boulevard , Houston, 
Texas 77030, or call (713) 792-7303 . 
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Fall and Winter Conferences 
Sponsored by The University of Texas M. D. Anderson Cancer Center 
October 11-14, 1988 
Forty-First Annual Symposium on Fundamental Cancer 
Research 
" Development and Differentiation: Modern Approaches 
to Classical Problems" 
Westin Galleria Hotel, Houston 
November 2-5, 1988 
Thirty-Second Annual Clinical Conference 
"Optimizing Management of Primary Bone Tumors: 
An International Symposium Emphasizing the 
Multi-Disciplinary Approach" 
M. D. Anderson Cancer Center 
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November 12, 1988 
Update on Ovarian Cancer 
M. D. Anderson Cancer Center 
January 12-14, 1989 
First Annual Conference on Outpatient Ministry 
"A.New Challenge in Pastoral Care" 
M. D. Anderson Cancer Center 
For more information, write Office of Conference Services, 
Box 131, The University ofTexas M. D. Anderson Cancer 
Center, 1515 Holcombe Boulevard, Houston, Texas 
77030, or call (713) 792-2222. 
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Cell Differentiation continued trom page s 
uterine epithelial cells and invades that tissue, a process 
similar to cancer metastasis; and Barry D. Shur, Ph.D., 
on how cell surface molecules provide information to 
the nucleus. 
This last question, how cells know where they are, "is 
becoming a fundamental issue," Lennarz said, "boiled 
down to: cells know where they are in response to the envi-
ronment because on the surface their binding molecules 
interact with molecules on nearby cells, or with molecules 
in the fluid around them . That binding process sends 
molecular signals into the cells, which end up turning 
genes on or off. A lot of the molecular details on how this 
works are not totally clear, but that seems to be the general 
strategy." 
How Are Genes Reguh1ted? 
The other theme of their work, perhaps broader and 
overlapping, Lennarz said, is, "How are genes turned on 
and off, how are they regulated~ Again, we're approaching 
this using mainly normal, not cancer, cells. What are the 
factors that cause a cell to become a muscle cell? That's a 
terminal differentiation event; after that the cell will prolif-
8 
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erate no more. It fuses with another cell, and they start 
making a structure that we would eventually recognize as 
muscle tissue. It's a program, and if the cell doesn ' t follow 
that program, it may become a cancer cell." 
Cell growth is the focus of much basic research around 
the world, most of it unrelated to cancer, he said. "Some 
cancer centers support research, some don ' t, and I think 
our institution deserves credit for the fact that, in addition 
to being known for the best possible cancer treatment, it 
recognizes that the future of cancer treatment is in basic 
research . '' 
And since scientists are wishful thinkers by profession, 
Lennarz would like to believe, he said, that the principles 
of growth control will be clarified in some great discovery, 
and that this will open the door to a whole new way of 
treating cancer. "No one has seen any direct sign of this 
yet, " he said, "and anyway ifl saw it, I hope I would be 
smart enough to make the discovery myself." ■ 
Physicians who desire additional information may write William J. 
Lennarz, Ph.D., Department of Biochemistry and Molecular Biology, 
Box 117, The University ofTexas M. D. Anderson Cancer Center, 1515 
Holcombe Boulevard, Houston, Texas 77030, or call (713) 792-8602 . 
